The trajectory of the erectile dysfunction drug presents a complex picture for those considering investment. While the initial launch generated substantial gains, the expiration of its exclusive rights opened the https://victornbxd503531.blogacep.com/47459149/the-copyright-and-big-pharma-a-volatile-bet